Associated Papers
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.
Wei L et al.
Molecular Therapy Oncolytics, 2020
The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
Kayastha GK et al.
British Journal of Haematology, 2017
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P et al.
Cancer Letters, 2016
Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Kaleem B et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2015
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S et al.
American Journal of Hematology, 2012
Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.
Tauchi T et al.
Oncogene, 2011
NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.
Wagh V et al.
Frontiers in Bioscience (elite Edition), 2011
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Chan WW et al.
Cancer Cell, 2011
In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.
Naito H et al.
Leukemia Research, 2006
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
Willis SG et al.
Blood, 2005
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP et al.
Cancer Cell, 2002
Select a paper to view details